Salvatore Pisconti

Salvatore Pisconti

Auto-generated profile, based on publicly available information

Salvatore Pisconti

Medical Oncology Unit, San Giuseppe Moscati Hospital, Statte, Italy

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2012 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Closed access
MGMichele Guida
Michele Guida
SPSalvatore Pisconti
Salvatore Pisconti
GCGiuseppe Colucci
Giuseppe Colucci
Introduction: Metastatic melanoma is one of the most resistant tumors to standard chemotherapy, with a median overall survival of 6 – 8 months. Previously approved drugs offer only marginal survival advantages. Advances in the understanding of melanoma biology and host immunity have recently opened the field to new therapeutic approaches. Thus, after many years of disappointing results, a new era in the treatment of melanoma is beginning. Areas covered: This review discusses new advances in the treatment of metastatic melanoma. Current data regarding the new agents under clinical development are reviewed, including emerging data from recently completed clinical trials, as well as preliminary data from ongoing studies testing novel therapeutic strategies. Expert opinion: The new agents specifically targeted against melanoma are changing the standard of care for this disease. The monoclonal antibody ipilimumab is the first new agent approved for first- and second-line treatment of metastatic melanoma, based on improved overall survival compared -with standard therapy. Other drugs, such as BRAF inhibitors, have demonstrated high activity in the advanced disease and will be reaching clinical approval. Researchers are already planning ways to combine some of these new drugs in order to render possible a longer control of tumor.

23 March 2012 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Closed access
DGDomenico Galetta
Domenico Galetta
ARAntonio Rossi
Antonio Rossi
SPSalvatore Pisconti
Salvatore Pisconti
GCGiuseppe Colucci
Giuseppe Colucci
Introduction: Most NSCLC patients are diagnosed in the advanced stage of the disease. Recently, chemotherapeutic agents have reached a plateau of effectiveness. Increased understanding of cancer biology has revealed several potential therapeutic strategies that have led to marketing of new biologic agents. The echinoderm microtubule-associated protein like-4–anaplastic lymphoma kinase (EML4–ALK) fusion oncogene represents one of the newest molecular targets in NSCLC, identifying a subset of NSCLC patients characterized by distinct clinicopathological features. Areas covered: The available results concerning ALK inhibitors for the treatment of advanced NSCLC patients. An electronic search was used to retrieve the articles addressing this topic. Expert opinion: In a pivotal Phase I clinical trial, crizotinib (PF-02341066), a small-molecule ALK inhibitor, demonstrated impressive antitumor activity in the majority of NSCLC patients with ALK fusions. Phase III randomized trials investigating crizotinib in this subgroup of patients are ongoing. If the results from these large international trials confirm the efficacy of crizotinib in the subset of patients, the next few years could see the treatment of advanced NSCLC patients with ALK fusions. Specific inhibitors would realize the so called personalized medicine in subsets of this disease.

1 March 2017 in Anti-Cancer Drugs
Verified
Journal Article
Closed access
FPFrancesco Perri
Francesco Perri
SPSalvatore Pisconti
Salvatore Pisconti
MFMatteo Favia
Matteo Favia
GSGiuseppina Della Vittoria Scarpati
Giuseppina Della Vittoria Scarpati
MCManuel Conson
Manuel Conson
GFGianfranco Favia
Gianfranco Favia
Oral cavity mucosal melanomas (OCMM) represent only 3% of all malignant melanomas. Surgery is the mainstay of treatments and it is often followed by adjuvant radiotherapy. The role of adjuvant immunotherapy and/or chemotherapy is still debated and to date neither treatment is routinely used. From January 1990 to January 2010, we have collected from our database data of 20 patients with a histologically proven diagnosis of OCMM. Upfront surgery, followed by adjuvant radiotherapy was performed in 16/20 (80%) patients. Immunohistochemical analysis was carried out on all tissue samples and the following markers were assessed: Ki-67, HMG-45, Melan-A, S-100, CD31, CD35, CD20, CD21, and CD3. Although Ki-67, HMG-45, Melan-A, and S-100 were assessed in tumor cells, the analysis of CD31, CD21, CD20, CD3, and CD35 was carried out on the tumor-infiltrating lymphocytes. Patient outcome was analyzed and associated with clinical and Immunohistochemical tumor characteristics. The median overall survival (OS) was 12 months, with a 2-year OS rate of 30%. The median progression-free survival (PFS) was 9 months, with a 2-year PFS rate of 25%. Grade of lymphocyte infiltration (CD20 and CD3 expression) correlated strongly with prognosis. Interestingly, overexpression of CD21 along with downregulation of CD31 was significantly associated with better OS and PFS, whereas the reversal features correlated with a poor prognosis. Our report shows that patients affected by OCMM have a poor prognosis despite the administration of multimodal treatments. Moreover, our analysis suggests that the evaluation of several biomarkers, especially in tumor-infiltrating lymphocytes, may identify categories of patients with distinct immune response against the tumor and possibly different treatment response and prognosis.

24 November 2017 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
FPFrancesco Perri
Francesco Perri
Francesco LongoFrancesco Longo
Francesco Longo
GSGiuseppina Della Vittoria Scarpati
Giuseppina Della Vittoria Scarpati
SPSalvatore Pisconti
Salvatore Pisconti
VLVito Longo
Vito Longo
RSRaffaele Solla
Raffaele Solla
Key Clinical Message: Pretherapy assessment has a crucial role in the management of advanced oropharyngeal carcinoma. The case report represents an example of how translational research may help to optimize the therapeutic options and to choose a well‐shaped therapy adapted to the tumor and the patient.

2 October 2026 in Clinical Colorectal Cancer
Verified
Journal Article
Closed access
ADAlessandra Pia D’AGata
Alessandra Pia D’AGata
GPGloria Pellizzari
Gloria Pellizzari
GMGiulia Martini
Giulia Martini
MGMichele Ghidini
Michele Ghidini
SNStefania Napolitano
Stefania Napolitano
DCDavide Ciardiello
Davide Ciardiello

29 January 2026 in Infectious Disorders - Drug Targets
Verified
Journal Article
Closed access
Leo GuidobaldiLeo Guidobaldi
Leo Guidobaldi
CCConcetta Cafiero
Concetta Cafiero
GSGiuseppina Stillitano
Giuseppina Stillitano
EREnzo Ricciardi
Enzo Ricciardi
LCLuigi Coppola
Luigi Coppola
SPSalvatore Pisconti
Salvatore Pisconti
Introduction: Although cases of squamous cell carcinoma of the cervix are declining, the increase in adenocarcinoma and in situ adenocarcinoma raises new concerns and requires improve-ments in diagnostic and therapeutic strategies. This study investigates the relationship between ad-vanced CIN3 and concurrent cervical glandular diseases, emphasising the importance of high-risk HPV genotypes in the progression of these conditions. Methods: The clinical data of 104 patients who underwent conization for CIN3 at our centre in the last 10 years were reviewed. Cytological and histological diagnoses were performed according to the 2014 Bethesda system and WHO classification criteria, respectively. The analysis included patient age, HPV genotype of the surgical specimen, length of the cone, resection margin status, and follow-up details. Results: Of the 104 patients, 92 (88.46%) were diagnosed with single CIN3 lesions (group 1), while 12 patients (11.54%) had coexisting glandular CIN3 lesions (group 2). All women tested were found to be positive for high-risk HPV (HPV-HR). The HPV18 genotype was found to be statistically more prevalent in group 2 (41.7%) than in group 1 (13%) (p = 0.011). At the first follow-up, HPV persis-tence was observed in 14/92 (15.2%) patients in group 1 and 10/12 (83.3%) patients in group 2 (p= 0.00001). Finally, the recurrence rate was 6.5% (6/92) in group 1 vs 30% (3/10) in group 2 (p= 0.012). Discussion: In the management of cervical lesions, glandular pathology may go undetected at initial diagnosis, as it is often not visible on colposcopy or cytology. It is only through excisional treatment, which allows a more detailed analysis of the tissue, that these lesions can be identified. The presence of an associated glandular lesion radically changes the clinical picture and therapeutic management, requiring a more radical approach than that expected for an isolated CIN3 lesion. Conclusions: The results of the study not only highlight the complexity of CIN3 associated with AIS/AC lesions, but also the importance of an integrated strategy that includes early diagnosis, ap-propriate treatment, and rigorous follow-up. The ultimate goal is the improvement of clinical out-comes and quality of life for cervical cancer patients.